There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Carisma Therapeutics (CARM – Research Report) with bullish sentiments.
Neurocrine (NBIX)
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Neurocrine today and set a price target of $155.00. The company’s shares closed last Tuesday at $140.12, close to its 52-week high of $148.37.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $152.14 average price target, implying a 7.9% upside from current levels. In a report issued on April 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $165.00 price target.
See the top stocks recommended by analysts >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX:
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink
